Company Encyclopedia
View More
name
Jyong Biotech
MENS.US
Jyong Biotech Ltd., a science-driven biotechnology company, develops and commercializes plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops MCS-2 for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bladder pain syndrome. The company was founded in 2002 and is headquartered in New Taipei City, Taiwan.
1.945 T
MENS.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    U.S. stock market midday update: Jyong Biotech's stock price plummets 10.17% as expansion into the Vietnamese market fails to gain favor

    Jyong Biotech fell 10.17%; Praxis Precision Medicines rose 30.81%, with a transaction volume of USD 603 million; Amgen fell 2.51%, with a transaction volume of USD 378 million; Precision Science rose 0.05%, with a transaction volume of USD 352 million; AbbVie fell 1.11%, with a market value of USD 399.7 billion

    Tracking Unusual Activity·
    US
    MENS
    +0.03%
    Tracking Unusual Activity·
    US
    MENS
    +0.03%

    Jyong Biotech Expands Regional Partnerships, Signs MoU With A Vietnam Pharmaceutical Distributor

    Dec 4 (Reuters) - Jyong Biotech Ltd:* JYONG BIOTECH EXPANDS REGIONAL PARTNERSHIPS, SIGNS MOU WITH A VIETNAM PHARMACEUTICAL DISTRIBUTOR FOR MCS-2 MARKET ENTRY Source text: Further company coverage:

    Reuters·
    US
    MENS
    +0.03%
    Reuters·
    US
    MENS
    +0.03%

    U.S. Stock Market Midday Update: Jyong Biotech's six-month increase exceeds 200%, active capital flow attracts market attention

    Jyong Biotech rose 15.13%; Q32 Bio rose 104.56%, with a transaction volume of USD 712 million; Cidara Therapeutics fell 0.13%, with a transaction volume of USD 390 million; Precision BioSciences rose 0.04%, with a transaction volume of USD 330 million; AbbVie fell 1.04%, with a market capitalization of USD 398.3 billion

    Tracking Unusual Activity·
    US
    MENS
    +0.03%
    Tracking Unusual Activity·
    US
    MENS
    +0.03%

    Jyong Biotech (NASDAQ:MENS) Shares Gap Up - Still a Buy?

    Jyong Biotech (NASDAQ:MENS) shares opened higher at $33.00 from a previous close of $30.36, last trading at $32.80. Despite the price increase, Weiss Ratings reiterated a 'sell' rating, and the stock has a consensus 'sell' rating. BNP Paribas Financial Markets recently acquired 1,698 shares. Jyong Biotech specializes in plant-derived drugs for urinary system diseases, targeting markets in the U.S., EU, and Asia.

    Market Beat·
    US
    MENS
    +0.03%
    Market Beat·
    US
    MENS
    +0.03%

    Jyong Biotech shares are trading higher after the company announced it has completed the statistical analysis of the primary efficacy endpoints in its current phase 2 clinical study of MCS-8 in Taiwan.

    benzinga_article·
    US
    MENS
    +0.03%
    benzinga_article·
    US
    MENS
    +0.03%
    © 2025 Longbridge｜Disclaimer